Applied Evidence

Is diabetes distress on your radar screen?

Author and Disclosure Information

 

References

Unlike MDD, diabetes distress has a specific cause—diabetes—and can best be understood as an emotional response to a demanding health condition.13 And, because the source of the problem is identified, diabetes distress can be treated with specific interventions targeting the areas causing the highest levels of stress.

When a psychiatric condition and diabetes distress overlap

MDD, anxiety disorders, and diabetes distress are all common in patients with diabetes,24 and the co-occurrence of a psychiatric disorder and diabetes distress is high.25 Thus, it is important not only to identify cases of diabetes distress but also to consider comorbid depression and/or anxiety in patients with diabetes distress.

More often, though, it is the other way around, according to the Distress and Depression in Diabetes (3D) study. The researchers recently found that 84% of patients with moderate or high diabetes distress did not fulfill the criteria for MDD, but that 67% of diabetes patients with MDD also had moderate or high diabetes distress.13,15,17,25

The data highlight the importance of screening patients with a dual diagnosis of diabetes and MDD for diabetes distress. Keep in mind that individuals diagnosed with both diabetes distress and a comorbid psychiatric condition may require more complex and intensive treatment than those with either diabetes distress or MDD alone.25

Screening for diabetes distress

Diabetes distress can be easily assessed using one of several patient-reported outcome measures. Six validated measures, ranging in length from one to 28 questions, are designed for use in primary care (TABLE).26-30 Some of the measures are easily accessible online; others require subscription to MEDLINE.

Summary of diabetes distress measures image

Pages

Recommended Reading

Examining the safety of lipid-lowering drugs in pregnancy
MDedge Family Medicine
New guidelines provide standardized hypoglycemia values for clinical evaluation
MDedge Family Medicine
Empagliflozin first antidiabetes drug to gain cardioprotective indication
MDedge Family Medicine
Diabetes treatment costs doubled in Sweden since 2006
MDedge Family Medicine
Landmark psychosocial guidelines for diabetes spark debate over the ideal vs. the practical
MDedge Family Medicine
FDA affirms bladder cancer warning with diabetes drug
MDedge Family Medicine
XR version of Synjardy gets FDA’s nod
MDedge Family Medicine
FDA expands indication for continuous glucose monitoring system
MDedge Family Medicine
ADA: Empagliflozin and liraglutide reduce type 2 CV death
MDedge Family Medicine
Diabetes, ischemic heart disease, pain lead health spending
MDedge Family Medicine